BNTX:NASDAQ
BioNTech SE - ADR
$96.06
arrow_downward
-2.64%(-2.60) 1D
$96.06
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 18, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
$98.81
High
$99.25
Low
$95.71
Mkt. cap
24.13B
Avg. vol.
1.45M
Volume
1.20M
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.70
Beta
1.27
Shares outstanding
251.20M
No. of employees
8K
Open
$98.81
High
$99.25
Low
$95.71
Mkt. cap
24.13B
Avg. vol.
1.45M
Volume
1.20M
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.70
Beta
1.27
Shares outstanding
251.20M
No. of employees
8K
News stories
From web sources and news partners
AD HOC NEWS
·
2 hours ago
BioNTech SE stock dips as CEO share sale and trial setback temper lung cancer optimism
Kalkine Media
·
14 hours ago
BioNTech CEO Ugur Sahin Executes Sale of 64,000 Shares Under 10b5-1 Plan
Stock Titan
·
16 hours ago
BioNTech (NASDAQ: BNTX) taps KPMG for 2027 audit, pending shareholder vote
The Motley Fool
·
1 day ago
BioNTech Threw in the Towel on Its Colorectal Cancer Vaccine Trial. Should Investors Be Worried?
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR